Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › relatlimab

relatlimab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of relatlimab

10 trials tracked of relatlimab.

10Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 10
  1. Phase 2 Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Completed
  2. Phase 2 Neoadjuvant and Adjuvant Checkpoint Blockade Completed
  3. Phase 2 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Completed
  4. Phase 2 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Completed
  5. Phase 2 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies Completed
  6. Phase 2 An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Completed
Show 4 more trials
  1. Phase 2 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Completed
  2. Phase 2 A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Completed
  3. Phase 2 An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Completed
  4. Phase 2 A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune checkpoint inhibitors increase risk of myocarditis and other cardiac toxicities in patients
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitors increase risk of myocarditis and other cardiac toxicities in patients Immune checkpoint inhibitors linked to increased risk of heart issues
This systematic review and network meta-analysis of 135 RCTs indicates that both PD-1/PD-L1 monotherapies and combination therapies increase…
Certain cancer treatments called immune checkpoint inhibitors are linked to a higher risk of heart inflammation and other serious cardiac pr…
Frontiers Aug 31, 2026